Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
buy vibrator.
Popular Articles

Compliance And Cost: Bitter Pills To Swallow In The Age Of Oral Chemotherapy
Though the growing shift toward oral chemotherapy agents offers cancer patients greater freedom and independence during their treatment, physicians say use of the new medications also poses more chances for patients to skip doses, miss prescription refills, and take their drugs in a dangerous way. An increasing number of cancer patients who receive chemotherapy now do so at home, with the click of a pill bottle each day rather than the drip of an IV medicine that must be delivered in a doctor"s office or hospital.
pharmacy online
Kai Sensors Receives FDA Clearance For Its Wireless, Non-Contact Respiratory Device
Hawaii-based Kai Sensors announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Kai Sensors Non-Contact Respiratory Rate Spot Check, also called the Kai RSpot. The 510(k) clearance allows Kai Sensors to market the Kai RSpot to physicians, hospitals, and clinics.
News of the day
The Cancer Institute Of New Jersey Network Of Hospitals At The Forefront Of Testing New Nationwide Data Reporting System
What if the quality of cancer care could be assessed and improved in "real clinical time" instead of waiting the typical two years it takes for clinical data to be analyzed and changes implemented? That is an opportunity The Cancer Institute of New Jersey (CINJ) Network of hospitals is exploring this summer, as it takes the lead in a national initiative to improve data collection on cancer treatment and create a new quality assessment system that can be utilized by health providers across the country. The CINJ Network of hospitals represents nearly a quarter of the 60 beta test sites from across the country that have been invited to help steer the effort. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.
Health Insurance

Progression Of Skeletal Muscle Disorder Slowed By Vaccine

A potential vaccine for Alzheimer"s disease also has been shown in mice to slow the weakening of muscles associated with inclusion body myositis, a disorder that affects the elderly. The finding brings new hope for IBM patients with weakness, inflammation or atrophy of muscles in their fingers, wrists, forearms or quadriceps. There is no cure for IBM, nor is there an effective treatment, according to the National Institutes of Health. "The immunization wasn"t a complete fix, but it significantly slowed the deterioration of motor function in our IBM mice," said Frank LaFerla, director of UC Irvine"s Institute for Brain Aging and Dementia. "I hope our discovery leads to clinical trials and, eventually, a vaccine for people suffering from or at risk for IBM." Study results appear in The Journal of Neuroscience. LaFerla and assistant project scientist Masashi Kitazawa tested the vaccine on 1-year-old mice with high levels of a protein called beta amyloid in their skeletal muscle tissue - a characteristic feature of IBM. After three months of treatment, the mice were producing antibodies against beta amyloid and had less of the protein in their muscles. Levels of oligomeric beta amyloid - a more toxic form - also were reduced. "It appears the antibodies helped remove beta amyloid or blocked its accumulation in muscle cells so they could stay healthy longer," Kitazawa said. Immunotherapy approaches such as vaccination are being extensively studied for Alzheimer"s in humans. In that disease, beta amyloid accumulates in the brain and leads to the creation of senile plaques, one of two signature Alzheimer"s lesions. Although immunotherapy has shown some benefit in human clinical trials, there are significant safety concerns. For example, about 6 percent of people develop encephalitis, or brain inflammation. LaFerla thinks it"s unlikely IBM patients would develop encephalitis: "With IBM, brain integrity is not compromised like it is with Alzheimer"s. We should be cautious, but there"s little reason to assume IBM patients would have the same problem." UCI scientists Vitaly Vasilevko and David Cribbs also worked on this study, supported by the NIH. Jennifer Fitzenberger University of California - Irvine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009